Modulation of poliovirus replicative fitness in HeLa cells by deoptimization of synonymous codon usage in the capsid region.
We replaced degenerate codons for nine amino acids within the capsid region of the Sabin type 2 oral poliovirus vaccine strain with corresponding nonpreferred synonymous codons. Codon replacements were introduced into four contiguous intervals spanning 97% of the capsid region. In the capsid region of the most highly modified virus construct, the effective number of codons used (N(C)) fell from 56.2 to 29.8, the number of CG dinucleotides rose from 97 to 302, and the G+C content increased from 48.4% to 56.4%. Replicative fitness in HeLa cells, measured by plaque areas and virus yields in single-step growth experiments, decreased in proportion to the number of replacement codons. Plaque areas decreased over an approximately 10-fold range, and virus yields decreased over an approximately 65-fold range. Perhaps unexpectedly, the synthesis and processing of viral proteins appeared to be largely unaltered by the restriction in codon usage. In contrast, total yields of viral RNA in infected cells were reduced approximately 3-fold and specific infectivities of purified virions (measured by particle/PFU ratios) decreased approximately 18-fold in the most highly modified virus. The replicative fitness of both codon replacement viruses and unmodified viruses increased with the passage number in HeLa cells. After 25 serial passages (approximately 50 replication cycles), most codon replacements were retained, and the relative fitness of the modified viruses remained well below that of the unmodified virus. The increased replicative fitness of high-passage modified virus was associated with the elimination of several CG dinucleotides. Potential applications for the systematic modulation of poliovirus replicative fitness by deoptimization of codon usage are discussed.
Burns
Cara Carthel
CC
Respiratory and Enteric Viruses Branch, G-10, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Rd., N.E., Atlanta, GA 30333, USA. cburns@cdc.gov
Shaw
Jing
J
Campagnoli
Ray
R
Jorba
Jaume
J
Vincent
Annelet
A
Quay
Jacqueline
J
Kew
Olen
O
D001483:Base Sequence; D002213:Capsid / Q000378:metabolism*; D003062:Codon; D006367:HeLa Cells; D006801:Humans; D016297:Mutagenesis, Site-Directed; D017955:Poliovirus / Q000235:genetics* / Q000254:growth & development / Q000502:physiology*; D011055:Poliovirus Vaccine, Oral / Q000235:genetics; D012367:RNA, Viral / Q000235:genetics; D010948:Viral Plaque Assay; D014771:Virion / Q000254:growth & development; D014779:Virus Replication
D003062:Codon; D011055:Poliovirus Vaccine, Oral; D012367:RNA, Viral